AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie Inc (NYSE:ABBV) will report second-quarter earnings on Thursday and Wall Street expects $2.96 in earnings per share and $14 billion in revenues as the company reports before market hours.
艾伯維公司（紐約證券交易所代碼：ABBV）將於週四公佈第二季度業績，華爾街預計每股收益爲2.96美元，收入爲140億美元，該公司在盤前公佈。
AbbVie investors and analysts will be focusing on the revenue impact of arthritis drug Humira following its U.S. patent expiry, after a significant first-quarter decline.
在第一季度大幅下滑之後，艾伯維的投資者和分析師將關注關節炎藥物Humira在美國專利到期後的收入影響。
Also, with new CEO Robert A. Michael at the helm and strong growth from Humira's replacements, investors will be looking for signs of recovery and market optimism.
此外，隨着新任首席執行官羅伯特·邁克爾的掌舵以及Humira接班人的強勁增長，投資者將尋找復甦和市場樂觀的跡象。
The stock is up 20.93% over the past year, 11.73% year-to-date.
該股在過去一年中上漲了20.93％，今年迄今爲止上漲了11.73％。
Let's look at what the charts indicate for AbbVie stock, and how the stock currently maps against Wall Street estimates.
讓我們來看看圖表對艾伯維股票的看法，以及該股目前與華爾街估計的對比情況。
AbbVie Stock Trend Bullish Ahead Of Q2 Earnings
艾伯維股票走勢在第二季度業績前看漲
AbbVie's stock shows a strongly bullish trend, with the share price of $173.15 surpassing its 5, 20, and 50-day exponential moving averages. This technical setup indicates a robust upward momentum.
艾伯維的股票顯示出強烈的看漲趨勢，173.15美元的股價超過了其5、20和50天的指數移動平均線。這種技術設置表明了強勁的上升勢頭。
Chart created using Benzinga Pro
使用 Benzinga Pro 創建的圖表
Specifically, the stock is trading above its 8-day ($171.43), 20-day ($169.69), 50-day ($166.47), and 200-day ($161.99) simple moving averages, signaling bullish conditions.
具體而言，該股的交易價格高於其8天（171.43美元）、20天（169.69美元）、50天（166.47美元）和200天（161.99美元）的簡單移動平均線，這表明看漲情況。
Chart created using Benzinga Pro
使用 Benzinga Pro 創建的圖表
The Moving Average Convergence Divergence (MACD) indicator, at 1.53, reinforces this bullish stance.
移動平均收斂散度（MACD）指標爲1.53，強化了這種看漲立場。
However, with an RSI of 57.65, and treading higher — the stock might be approaching overbought territory, suggesting caution.
但是，由於RSI爲57.65，並且正在走高，該股可能接近超買區域，這表明謹慎行事。
The Bollinger Bands further support a bullish outlook, with the 25-day bands at $164.88 to $175.13 and the stock trading in the upper band.
布林帶進一步支撐了看漲前景，25天區間爲164.88美元至175.13美元，股票交易處於上限。
Despite the current selling pressure, which could imply potential for bearish movement, the overall technical indicators favor a bullish position for AbbVie stock.
儘管目前存在拋售壓力，這可能意味着可能出現看跌走勢，但總體技術指標有利於艾伯維股票的看漲頭寸。
Read Also: AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
另請閱讀：艾伯維就 “長期存在的” AndroGel案中的律師-委託人特權向最高法院提出上訴
AbbVie Analysts Consensus Ratings
艾伯維分析師共識評級
Ratings & Consensus Estimates: The consensus analyst rating on AbbVie stock stands at an Overweight currently with a price target of $173. Recent analyst ratings from BMO Capital, Morgan Stanley, and Cantor Fitzgerald, in July, have an average price target of $203.33 for AbbVie stock, implying a potential 17.67% upside.
評級和共識估計：分析師對AbbVie股票的共識評級目前爲增持，目標股價爲173美元。BMO Capital、摩根士丹利和坎託·菲茨傑拉德最近在7月份的分析師評級將艾伯維股票的平均目標股價定爲203.33美元，這意味着可能上漲17.67％。
ABBV Price Action: AbbVie stock was trading at $172.80 at the time of publication.
ABBV價格走勢：在發佈時，艾伯維股票的交易價格爲172.80美元。
- Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
- 大型製藥公司準備接管大麻嗎？在美國已經有三家公司管理十分之八的藥品處方